Prevent program: preclinical efficacy and intermediate endpoint biomarkers; task order title: preclinical development of an RNA vaccine for immunoprevention of prostate cancer
Ended Awarded Last action
- Contract number
- 75N91020F00001
- Awardee
-
IIT Research Institute UEI DGBUFQYMKWB5 Part of Illinois Institute Of Technology
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,736,011
Award facts
- Opportunity
- Contract value 100% obligated
- $1,736,011.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Chicago, IL 60616, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$6,373 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $1,020,618 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $291,405 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $430,361 |
Show all 11
About this award
The National Cancer Institute awarded a $1.74 million firm fixed-price delivery order to IIT Research Institute (IITRI) on September 8, 2020, for preclinical development of an RNA vaccine for immunoprevention of prostate cancer under the PREVENT Preclinical Drug Development Program. The work, to be performed in Chicago, Illinois, is scheduled for completion by May 7, 2025, with no small business set-aside designation applied. IITRI, a non-profit contract research organization and subsidiary of Illinois Institute of Technology, specializes in preclinical drug development services and brings extensive capabilities in preclinical efficacy assessments and biomarker evaluation to support the vaccine development pipeline.
This delivery order falls under the larger PREVENT Cancer Preclinical Drug Development Program IDIQ vehicle with the National Cancer Institute, which carries a potential value of approximately $150 million and enables efficient task order access to IITRI's specialized preclinical research services. The assignment leverages IITRI's established expertise in conducting preclinical studies including dose range finding, safety evaluations, efficacy assessments, and supporting investigational new drug application requirements across various therapeutic areas. The organization's focus on delivering sophisticated research and development services positions it to advance early-stage development of this novel immunotherapeutic approach for prostate cancer prevention.
Quick answers
Who was awarded contract 75N91020F00001?
75N91020F00001 was awarded to IIT Research Institute by National Cancer Institute (National Institutes of Health) on September 8, 2020.
How much is contract 75N91020F00001 worth?
The government has obligated $1,736,011 on 75N91020F00001.
Is contract 75N91020F00001 an order under another contract?
Yes. 75N91020F00001 is a delivery order under 75N91019D00012, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91020F00001 competed?
The extent of competition for 75N91020F00001 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award